An Open-label, Phase 1 Study to Characterize the Effects of a Strong CYP3A4 Inducer on the Pharmacokinetics of MK-8527 in Healthy Adult Participants
Latest Information Update: 28 Mar 2025
At a glance
- Drugs MK-8527 (Primary) ; Carbamazepine
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 28 Mar 2025 New trial record